Allgemeine Maßnahmen und Management der PAH in besonderen Situationen

Zusammenfassung

Allgemeine Therapiemaßnahmen und besondere Situationen wurden bei der 7. Weltkonferenz für Pulmonale Hypertonie von der neunten Taskforce bearbeitet. Sie konzentrierte sich v. a. auf die Patient*innenperspektive, allgemeine und supportive Maßnahmen und bei Patient*innen bestehende herausfordernde Bedingungen. Bei letzteren werden insbesondere die perioperative Versorgung, das Management während der Schwangerschaft, Medikamentenadhärenz, Palliativversorgung und der Einfluss des Klimas auf die Erkrankung beleuchtet. Darüber hinaus werden in dieser Arbeit einige Themen zusätzlich angesprochen, die in diesen Kontext fallen, jedoch nicht bei der Weltkonferenz Berücksichtigung fanden, wie z. B. Ernährung bei pulmonaler Hypertonie, Reisen und Einsatz kardiovaskulärer Medikamente.

Abstract

General measures and special conditions were addressed by the ninth task force at the 7^th World Symposium on Pulmonary Hypertension. It focused primarily on the patient perspective, general and supportive measures, and challenging patient conditions. Regarding the latter, particular attention was paid to perioperative care, management during pregnancy, medication adherence, palliative care, and the sinfluence of climate on the disease. Furthermore, this paper addresses several additional topics that fall within this context but were not addressed at the World Symposium, such as nutrition in pulmonary hypertension, travel, and the use of cardiovascular drugs.

Schlüsselwörter

pulmonalarterielle Hypertonie - Unterstützung - Management - Risikosituation

Keywords

pulmonary arterial hypertension - support - management - risk circumstances

Publication History

Article published online:
06 October 2025

• Literatur

• 1 Ford HJ, Brunetti C, Ferrari P. et al. Exploring the patient perspective in pulmonary hypertension. Eur Respir J 2024; 64: 2401129
• 2 Chin KM, Gaine SP, Gerges C. et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J 2024; 64: 2401325
• 3 Preston IR, Howard LS, Langleben D. et al. Management of pulmonary hypertension in special conditions. Eur Respir J 2024; 64: 2401180
• 4 Tsai CY, Shen CW, Lai HL. et al. Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: A nationwide, new-user cohort study. Front Pharmacol 2022; 13: 1030693
• 5 Qadus S, Naser AY, Ofori-Asenso R. et al. Adherence and Discontinuation of Disease-Specific Therapies for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2023; 23: 19-33
• 6 Schikowski EM, Swabe G, Chan SY. et al. Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension. J Am Heart Assoc 2022; 11: e026620
• 7 Omura J, Makanji Y, Tanabe N. et al. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study. Pulm Ther 2023; 9: 511-526
• 8 Kim NH, Hemnes AR, Chakinala MM. et al. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant 2021; 40: 279-288
• 9 Grill S, Bruderer S, Sidharta PN. et al. Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Br J Clin Pharmacol 2020; 86: 2424-2434
• 10 Csonka D, Fishman V, Natarajan J. et al. Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic. Pharmacol Res Perspect 2021; 9: e00846
• 11 Galie N, Hoeper MM, Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 34: 1219-1263
• 12 Galie N, Hoeper MM, Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Internat. Eur Heart J 2009; 30: 2493-2537
• 13 Kwant CT, Van Der Horst FAL, Bogaard HJ. et al. Nutritional status in pulmonary arterial hypertension. Pulm Circ 2022; 12: e12173
• 14 Brittain EL, Lindsey A, Burke K. et al. Carnitine consumption and effect of oral supplementation in human pulmonary arterial hypertension: A pilot study. Pulm Circ 2024; 14: e12425
• 15 Egenlauf B, Braun M, Schiffer V. et al. Right ventricular function in pulmonary hypertension and obesity – a cross-sectional cohort study with survival follow-up2024. Clin Res Cardiol 2025;
• 16 Grünig E, Jansa P, Fan F. et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2024; 83: 473-484
• 17 Reimann L, Preiss H, Müller J. et al. Medication adherence and clinical outcome in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension. BMJ Open Respiratory Research 2025; 12: e003023
• 18 Swetz KM, Shanafelt TD, Drozdowicz LB. et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transplant 2012; 31: 1102-1108
• 19 Hrustanovic-Kadic M, Ziegler C, El-Kersh K. Palliative Care Perception in Pulmonary Arterial Hypertension: Evaluating the Interaction of PPCI, PAH-SYMPACT Questionnaire, and the REVEAL 2.0 Risk Score. Ann Am Thorac Soc 2021; 18: 361-364
• 20 Rhee LS, Morgan AA, Dubrock HM. Palliative Care and Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension 2022; 21: 7-11
• 21 Quinn KL, Hsu AT, Smith G. et al. Association Between Palliative Care and Death at Home in Adults With Heart Failure. J Am Heart Assoc 2020; 9: e013844
• 22 Olsson KM, Delcroix M, Ghofrani HA. et al. Anticoagulation and Survival in Pulmonary Arterial Hypertension. Circulation 2014; 129: 57-65
• 23 Hoeper MM, Badesch DB, Ghofrani HA. et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023; 388: 1478-1490
• 24 Humbert M, McLaughlin V, Gibbs JSR. et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384: 1204-1215
• 25 Thaete LG, Khan S, Synowiec S. et al. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci 2012; 91: 583-586
• 26 Egenlauf B, Benjamin N, Resag C. et al. Fluid restriction in patients with pulmonary arterial hypertension and right heart failure. Eur Respir J 2024; 64 (Suppl. 68) PA4302
• 27 Ulrich S, Hasler ED, Saxer S. et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur Heart J 2017; 38: 1159-1168
• 28 Benjamin N, Echampati I, Harutyunova S. et al. Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study. Scientific Reports 2024; 14: 22038
• 29 Provencher S, Herve P, Jais X. et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126
• 30 Waligora M, Kurzyna M, Mularek-Kubzdela T. et al. Effects of beta-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study: The Database of Pulmonary Hypertension in the Polish Population (BNP-PL). Chest 2025; 167: 1171-1181
• 31 Nassif ME, Qintar M, Windsor SL. et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure. Circulation 2021; 143: 1673-1686
• 32 Florea A, Benjamin N, Eichstaedt C. et al. Effekt von SGLT2 Inhibitoren bei Patienten mit pulmonal-arterieller Hypertonie und kardialen Komorbiditäten. Pneumologie 2025; 79: S117-S118
• 33 Xanthouli P, Gordjani O, Benjamin N. et al. Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension. Scientific Reports 2023; 13: 1839
• 34 Luks AM. Can patients with pulmonary hypertension travel to high altitude?. High Alt Med Biol 2009; 10: 215-219
• 35 Roubinian N, Elliott CG, Barnett CF. et al. Effects of Commercial Air Travel on Patients With Pulmonary Hypertension. Chest 2012; 142: 885-892
• 36 Mohr LC. Hypoxia During Air Travel in Adults With Pulmonary Disease. Am J Med Sci 2008; 335: 71-79
• 37 Schneider S, Lichtblau M, Furian M. et al. Cardiorespiratory Adaptation to Short-Term Exposure to Altitude vs. Normobaric Hypoxia in Patients with Pulmonary Hypertension. J Clin Med 2022; 11: 2769
• 38 Yogeswaran A, Grimminger J, Tello K. et al. Air travel in patients suffering from pulmonary hypertension – A prospective, multicentre study. Pulm Circ 2024; 14: e12397
• 39 Schneider SR, Müller J, Bauer M. et al. Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy. Eur Heart J 2024; 45: 309-311
• 40 Lichtblau M, Schwarz EI, Ulrich T. et al. Effect of an Overnight Stay at 2500 m on Nocturnal Hypoxemia and Sleep-disordered Breathing in Patients with Pulmonary Vascular Disease: A Randomized Trial. Ann Am Thorac Soc 2025; 22: 1053-1061
• 41 Meyer S, McLaughlin VV, Seyfarth HJ. et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013; 41: 1302-1307
• 42 Deljou A, Sabov M, Kane GC. et al. Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. J Cardiothorac Vasc Anesth 2020; 34: 1506-1513
• 43 Ramakrishna G, Sprung J, Ravi BS. et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45: 1691-1699
• 44 Rajagopal S, Ruetzler K, Ghadimi K. et al. Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association. Circulation 2023; 147: 1317-1343
• 45 McGlothlin DP, Granton J, Klepetko W. et al. ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. J Heart Lung Transplant 2022; 41: 1135-1194
• 46 Marcus B, Marynen F, Fieuws S. et al. The perioperative use of inhaled prostacyclins in cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 2023; 70: 1381-1393
• 47 Yadav KN, Gabler NB, Cooney E. et al. Approximately One In Three US Adults Completes Any Type Of Advance Directive For End-Of-Life Care. Health Aff (Millwood) 2017; 36: 1244-1251
• 48 Greer JA, Applebaum AJ, Jacobsen JC. et al. Understanding and Addressing the Role of Coping in Palliative Care for Patients With Advanced Cancer. J Clin Oncol 2020; 38: 915-925
• 49 Kavalieratos D, Corbelli J, Zhang D. et al. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis. JAMA 2016; 316: 2104-2114
• 50 Rabow M, Kvale E, Barbour L. et al. Moving upstream: a review of the evidence of the impact of outpatient palliative care. J Palliat Med 2013; 16: 1540-1549
• 51 Higginson IJ, Bausewein C, Reilly CC. et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2: 979-987
• 52 Basch E, Deal AM, Dueck AC. et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 2017; 318: 197-198
• 53 National Coalition for Hospice and Palliative Care. NewsCAP: National Coalition for Hospice and Palliative Care issues updated guidelines. Am J Nurs 2019; 119: 15
• 54 Lewis RA, Armstrong I, Bergbaum C. et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. Eur Respir J 2021; 572000124
• 55 Whitmee S, Haines A, Beyrer C. et al. Safeguarding human health in the Anthropocene epoch: report of The Rockefeller Foundation-Lancet Commission on planetary health. Lancet 2015; 386: 1973-2028
• 56 Masnoon N, Shakib S, Kalisch-Ellett L. et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 230
• 57 World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003
• 58 Chaseling GK, Iglesies-Grau J, Juneau M. et al. Extreme Heat and Cardiovascular Health: What a Cardiovascular Health Professional Should Know. Can J Cardiol 2021; 37: 1828-1836
• 59 Gasparrini A, Guo Y, Hashizume M. et al. Mortality risk attributable to high and low ambient temperature: a multicountry observational study. Lancet 2015; 386: 369-375
• 60 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-3731